Therapeutic Benefits and Adverse Effects of Combined Pro-Angiogenic Gene Therapy in Mouse Critical Leg Ischemia.: Combined Pro-Angiogenic Gene Therapy in Leg Ischemia

Résumé : Objective: Critical leg ischemia (CLI) represents the ultimate stage of peripheral arterial disease. Despite current surgery advances, patients with CLI have limited therapeutic options. Therapeutic angiogenesis thus appears as a powerful approach, aiming to stimulate vessel formation by angiogenic molecules administration. In this context, combined gene therapy has proved the most efficient. The present study aims to compare, in a preclinical mouse model, the therapeutic benefit of a combination of two angiogenic factors FGF2 (fibroblast growth factor 2) and Cyr61 using plasmid and viral vectors, able to generate short or long-term transgene expression in the leg, respectively. Methods: Two therapeutic genes, FGF2 and Cyr61, were introduced into IRES-based expression vectors (FGFiCyr) allowing co-expression of the two transgenes. The pro-angiogenic plasmid pC-FGFiCyr was assessed by intramuscular administration followed by electrotransfer into ischemic legs. To generate long-term transgene expression, the FGFiCyr bicistronic cassette was introduced into an adeno-associated virus-derived vector (rAAV). The rAAV treatment was performed either before, or immediately after, surgery. Therapeutic effects were analyzed by laser doppler imaging, clinical score and angiography. Results: The plasmid pC-FGFiCyr improved revascularization, reperfusion and clinical score. Surprisingly, when AAV-FGFiCyr was injected 21 or 28 days before surgery, the pro-angiogenic rAAV was drastically deleterious on all measured parameters. In contrast, when administrated shortly after surgery, AAV-FGFiCyr generated therapeutic benefits, with a significantly better clinical score than after treatment with the plasmid. Conclusions: Therapeutic effects of the angiogenic combination FGF2-Cyr61 is observed with short term transgene expression, but the treatment is significantly more efficient when a long-term expression viral vector is used. However, the rAAV FGFiCyr generated therapeutic benefit only when injected in an ischemic leg, whereas the same dose of rAAV exhibited deleterious effects when administrated to healthy animals. These data may contribute to the understanding of the moderate success of pro-angiogenic treatments in CLI gene therapy clinical assays.
Type de document :
Article dans une revue
Annals of Vascular Surgery, Elsevier Masson, 2016, pii: S0890-5096(16)31264-X. Epub ahead of print. 〈10.1016/j.avsg.2016.08.027〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01424778
Contributeur : Anne-Catherine Prats <>
Soumis le : lundi 2 janvier 2017 - 19:20:27
Dernière modification le : mercredi 4 janvier 2017 - 01:01:44

Fichier

Lebas et al Ann Vasc Surg HAL....
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Benoît Lebas, Julien Galley, Edith Renaud-Gabardos, Françoise Pujol, Françoise Lenfant, et al.. Therapeutic Benefits and Adverse Effects of Combined Pro-Angiogenic Gene Therapy in Mouse Critical Leg Ischemia.: Combined Pro-Angiogenic Gene Therapy in Leg Ischemia. Annals of Vascular Surgery, Elsevier Masson, 2016, pii: S0890-5096(16)31264-X. Epub ahead of print. 〈10.1016/j.avsg.2016.08.027〉. 〈inserm-01424778〉

Partager

Métriques

Consultations de la notice

138

Téléchargements de fichiers

60